Physician
Naspac1 LLC
Naspac1 LLC was paid $16.33M by Medicaid between Jan 2018 and Dec 2024, across 58 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 31% of everything it billed.
33Billing provider infoNASPAC1 LLC
HAINESPORT, NJ 08036
HAINESPORT, NJ 08036
33aNPI1528483245assigned 03/04/2014
33bProvider typeOrthopaedic Surgery Physician
28Total paid$16.33M
24GClaims347,895
24DCodes billed58
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Orthopaedic Surgery Physician providers in New Jersey
Rank by total paid#1 of 61
Median peer was paid$50K
This provider vs. median327×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,606 | $2.40M | |
| 2019 | 33,503 | $2.09M | |
| 2020 | 41,296 | $1.91M | |
| 2021 | 54,463 | $3.08M | |
| 2022 | 59,606 | $2.62M | |
| 2023 | 58,623 | $2.48M | |
| 2024incomplete | 55,798 | $1.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 31% | 92,167 | 83,745 | $5.01M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 27% | 70,782 | 61,785 | $4.42M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 20% | 91,834 | 82,781 | $3.31M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.4% | 3,528 | 3,492 | $559K |
| 64483 | 3.3% | 2,349 | 2,211 | $545K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.9% | 14,103 | 10,356 | $472K |
| 64493 | 2.0% | 2,075 | 1,958 | $334K | |
| L0648 | Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 1.4% | 502 | 492 | $227K |
| 99443 | 1.3% | 4,621 | 4,114 | $207K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.1% | 12,200 | 10,665 | $175K |
| 64494 | <1% | 1,974 | 1,857 | $140K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 9,195 | 8,563 | $126K |
46 more codes
| 64495 | <1% | 1,603 | $116K | |
| E0730 | Transcutaneous electrical nerve stimulation (tens) device, four or more leads, for multiple nerve stimulation | <1% | 623 | $104K |
| A4595 | Electrical stimulator supplies, 2 lead, per month, (e.g., tens, nmes) | <1% | 2,760 | $103K |
| 64635 | <1% | 204 | $74K | |
| 64484 | <1% | 769 | $61K | |
| 99454 | <1% | 885 | $49K | |
| 64636 | <1% | 207 | $47K | |
| 99457 | <1% | 893 | $40K | |
| 98977 | <1% | 705 | $35K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 288 | $28K |
| 80305 | <1% | 2,487 | $24K | |
| 99426 | <1% | 3,356 | $17K | |
| 99205 | Prolong outpt/office vis | <1% | 68 | $15K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 387 | $15K |
| 20610 | <1% | 188 | $11K | |
| 80306 | <1% | 531 | $11K | |
| 72275 | <1% | 797 | $11K | |
| 99458 | <1% | 258 | $9K | |
| 64490 | <1% | 60 | $8K | |
| 99442 | <1% | 2,501 | $7K | |
| 98975 | <1% | 401 | $6K | |
| 62321 | <1% | 38 | $5K | |
| 64491 | <1% | 59 | $3K | |
| 95911 | <1% | 15 | $3K | |
| 95886 | <1% | 16 | $3K | |
| L3031 | Foot, insert/plate, removable, addition to lower extremity orthosis, high strength, lightweight material, all hybrid lamination/prepreg composite, each | <1% | 32 | $2K |
| 77003 | <1% | 1,149 | $2K | |
| 99453 | <1% | 113 | $2K | |
| 64492 | <1% | 31 | $2K | |
| 99406 | <1% | 67 | $1K | |
| 98980 | <1% | 46 | $929.58 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 5,793 | $848.81 |
| 99407 | <1% | 25 | $749.73 | |
| E0720 | Transcutaneous electrical nerve stimulation (tens) device, two lead, localized stimulation | <1% | 33 | $724.62 |
| 99358 | Prolong nursin fac eval 15m | <1% | 39 | $648.54 |
| 98981 | <1% | 23 | $451.49 | |
| 95923 | <1% | 12 | $329.31 | |
| 95921 | <1% | 12 | $276.77 | |
| 98967 | <1% | 493 | $242.53 | |
| 99441 | <1% | 19 | $98.24 | |
| 77002 | <1% | 30 | $75.66 | |
| 99424 | <1% | 160 | $62.49 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 43 | $17.96 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 137 | $3.80 |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 0% | 115 | $0.00 |
| 82570 | 0% | 14,094 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOGDOL, RENEE (OFFICE MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Naspac-Nj PLLC | Paoli, PA | $1.42M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.